Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Joanna, Placzke"'
Autor:
Mateusz Ziomek, Joanna Placzke, Konrad Urbanek, Tomasz Skóra, Piotr Rutkowski, Mateusz Jacek Spałek
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 16 (2024)
Ewing sarcoma is a rare malignant neoplasm that primarily affects bone in children. Extraskeletal location is less common, while intradural extramedullary Ewing sarcoma (IEES) in adults is a casuistic phenomenon. Due to its rarity, a standardized tre
Externí odkaz:
https://doaj.org/article/2ae2690d9889419998509b130fb2ee4f
Autor:
Joanna Placzke, Paweł Teterycz, Pietro Quaglino, Bozena Cybulska-Stopa, Marco Tucci, Marco Rubatto, Tomasz Skora, Valeria Interno, Magdalena Rosinska, Aneta Borkowska, Anna Szumera-Cieckiewicz, Mario Mandala, Piotr Rutkowski
Publikováno v:
Cancers; Volume 14; Issue 23; Pages: 5763
Stage IV melanoma patients develop melanoma brain metastases (MBM) in 50% of cases. Their prognosis is improving, and its understanding outside the context of clinical trials is relevant. We have retrospectively analyzed the clinical data, course of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b7bdae51c668aeb6606e57fa55d4d701
https://hdl.handle.net/2318/1890883
https://hdl.handle.net/2318/1890883
Autor:
Amelia M. Taylor, Claire Galea, Serigne N. Lo, Florentia Dimitriou, Sarah Jacques, Clara Allayous, Hui-Ling Yeoh, Julia M. Ressler, Katharina C. Kähler, Lucia Festino, Julia Katharina Schwarze, Alexandre M. Wicky, Joanna Placzke, Douglas Buckner Johnson, Lisa Zimmer, Celeste Lebbe, Reinhard Dummer, Matteo S. Carlino, Georgina V. Long, Alexander M. Menzies
9575 Background: Both anti-PD-1 antibodies and BRAK/MEK inhibitors (BRAF/MEKi) reduce the risk of recurrence for patients with resected stage III melanoma. For patients with V600 BRAF-mutated melanoma who recur with resectable disease on or after adj
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0bf72b6e982a388643a2a5df2663d160
Autor:
Anna Małgorzata Czarnecka, Paweł Sobczuk, Paweł Rogala, Tomasz Świtaj, Joanna Placzke, Katarzyna Kozak, Anna Mariuk-Jarema, Mateusz Spałek, Monika Dudzisz-Śledź, Paweł Teterycz, Aneta Borkowska, Piotr Rutkowski
Publikováno v:
Cancer immunology, immunotherapy : CII. 71(8)
Immunotherapy (ITH) holds the possibility of tumor burden decrease after initial RECIST 1.1 defined progression. The clinical concept of treating selected patients (pts) beyond disease progression (PD) is supported by so-called pseudoprogression phen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::43a616ea0bf78912e7829a3e9bfdc5b7
https://pubmed.ncbi.nlm.nih.gov/35075516
https://pubmed.ncbi.nlm.nih.gov/35075516
Publikováno v:
Oncology in Clinical Practice. 14:28-33
Nowe terapie stosowane w leczeniu chorych na czerniaka wydluzyly czas przezycia chorych i wplynely na poprawe jakości ich zycia. Przedstawiono przypadek chorej, u ktorej w wykonanym rezonansie magnetycznym potwierdzono obecnośc pojedynczego ogniska
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2c9c550703ec3d8acf82044a729bba86
https://doi.org/10.5603/ocp.2018.0066
https://doi.org/10.5603/ocp.2018.0066
Autor:
Monika Dudzisz-Śledź, Tomasz Switaj, Mateusz Spałek, Katarzyna Kozak, Paweł Teterycz, Paweł Sobczuk, Piotr Rutkowski, Joanna Placzke, Paweł Rogala, Hanna Koseła-Paterczyk, Anna M. Czarnecka, Aneta Borkowska
Publikováno v:
Journal of Clinical Oncology. 39:e21541-e21541
e21541 Background: Immunotherapy (ITH) holds the possibility of tumor burden decrease after initial RECIST defined progression (PD). Clinical concept of treating of selected patients (pts) beyond PD is supported by this pseudoprogression phenomenon.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e746ed81104244d4da65aa401d4b37cc
https://doi.org/10.1200/jco.2021.39.15_suppl.e21541
https://doi.org/10.1200/jco.2021.39.15_suppl.e21541
Autor:
Jean-Yves Blay, Charlotte Benson, Piotr Rutkowski, Heribert Juergens, Hans Gelderblom, Ian Judson, Henk van den Berg, Meybrit Rasper, Uta Dirksen, Joanna Placzke, Annemiek M. van Maldegem
Publikováno v:
Pediatric Blood & Cancer. 62:40-44
BackgroundPatients with Ewing sarcoma (EWS) who develop refractory or relapsed disease have limited treatment options. In some sarcoma centres in Europe the combination of etoposide with carbo- or cisplatin is being used for these patients, however,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c609a3b1602fa5a2e768dd6e12c952e3
https://doi.org/10.1002/pbc.25230
https://doi.org/10.1002/pbc.25230
Autor:
Annemiek M, van Maldegem, Charlotte, Benson, Piotr, Rutkowski, Jean-Yves, Blay, Henk, van den Berg, Joanna, Placzke, Meybrit, Rasper, Ian, Judson, Heribert, Juergens, Uta, Dirksen, Hans, Gelderblom
Publikováno v:
Pediatric bloodcancer. 62(1)
Patients with Ewing sarcoma (EWS) who develop refractory or relapsed disease have limited treatment options. In some sarcoma centres in Europe the combination of etoposide with carbo- or cisplatin is being used for these patients, however, there are
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::d999e3fdf7760a6c9b79fc8a55926fec
https://pubmed.ncbi.nlm.nih.gov/25251256
https://pubmed.ncbi.nlm.nih.gov/25251256
Autor:
Rutkowski, Piotr, Ostaszewski, Krzysztof, Borkowska, Aneta, Katarzyna, Kozak, Joanna, Placzke, Tomasz, Switaj, Pawel, Rogala, Iwona, Kalinowska, Hanna, Kosela-Paterczyk, Zaborowski, Konrad, Teterycz, Pawel, Tysarowski, Andrzej, Makuła, Donata, Szumera-Ciećkiewicz, Anna, Czarnecka, Anna
Publikováno v:
European Journal of Surgical Oncology; Feb2022, Vol. 48 Issue 2, pe149-e149, 1p
Autor:
Ziomek, Mateusz, Placzke, Joanna, Urbanek, Konrad, Skóra, Tomasz, Rutkowski, Piotr, Spałek, Mateusz Jacek
Publikováno v:
Therapeutic Advances in Medical Oncology; 11/16/2024, p1-10, 10p